Back Bay Life Science Advisors analyzed the United States biosimilars market for our latest white paper, US Biosimilars: Opportunities and Challenges.
For nearly a decade, biosimilars have loomed large over every facet of the US healthcare debate. Depending on where you sit, biosimilars represent either a dreaded threat to innovation or a hoped-for answer to sky-high drug prices. However, neither scenario has fully come to pass, and although we still expect biosimilars to effect change in the biologics market, when it will happen and to what degree are still unknown. In this white paper we outline trends and potential scenarios for US biosimilars based on current European and US market dynamics. We examine the biosimilar landscape and conclude with thoughts on how developers of biologics can best adapt to an evolving market.